Effects of empagliflozin on skeletal muscle degradation in patients with heart failure: a prospective observational study
Sodium–glucose cotransporter-2 inhibitors (SGLT2i) are a cornerstone of contemporary heart failure (HF) therapy and provide consistent prognostic benefit, including in older, frail, and underweight patients. However, whether SGLT2i adversely affect skeletal muscle through accelerated muscle degradation remains in...